Compare Royalty Pharma plc Class A Ordinary Shares (RPRX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royalty Pharma plc Class A Ordinary Shares vs State Street SPDR S&P Biotech ETF — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 2.5× State Street SPDR S&P Biotech ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 1 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| RPRX | XBI | |
|---|---|---|
Market Cap | $25.27B | $10.11B |
Volume | 3,671,183 | 12,903,266 |
Sector | Health | Broad Market / Factor |
52-Week High | $63.96 | $169.55 |
52-Week Low | $35.44 | $104.99 |
Typical Hold Time | 1 Days | 38 Days |
Enterprise Value | $32.50B | — |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
